Soluble cerebral Aβ protofibrils link Aβ plaque pathology to changes in CSF Aβ42/Aβ40 ratios, neurofilament light and tau in Alzheimer’s disease model mice
The Aβ<sub>42</sub>/Aβ<sub>40</sub> ratio in the cerebrospinal fluid (CSF) and the concentrations of neurofilament light (NfL) and total tau (t-tau) are changed in the early stages of Alzheimer's disease (AD)<sup>1</sup>, but their neurobiological correlates are not entirely understood. Here, we used 5xFAD transgenic mice to investigate the associations between these CSF biomarkers and measures of cerebral Aβ, including Aβ<sub>42</sub>/Aβ<sub>40</sub> ratios in plaques, insoluble fibrillar deposits and soluble protofibrils. A high Aβ<sub>42</sub>/Aβ<sub>40</sub> ratio in soluble protofibrils was the strongest independent predictor of low CSF Aβ<sub>42</sub>/Aβ<sub>40</sub> ratios and high CSF NfL and t-tau concentrations when compared to Aβ<sub>42</sub>/Aβ<sub>40</sub> ratios in plaques and insoluble fibrillar deposits. Furthermore, the Aβ<sub>42</sub>/Aβ<sub>40</sub> ratio in soluble protofibrils fully mediated the associations between the corresponding ratio in plaques and all the investigated CSF biomarkers. In App<sup>NL-G-F/NL-G-F</sup> knock-in mice, protofibrils fully mediated the association between plaques and the CSF Aβ<sub>42</sub>/Aβ<sub>40</sub> ratio. Together, the results suggest that the Aβ<sub>42</sub>/Aβ<sub>40</sub> ratio in CSF might better reflect brain levels of soluble Aβ protofibrils than insoluble Aβ fibrils in plaques in AD. Furthermore, elevated concentrations of NfL and t-tau in CSF might be triggered by increased brain levels of soluble Aβ protofibrils.
Authors
- Lars Lannfelt (ORCID: https://orcid.org/0000-0001-9839-659X)
- Jörg Hanrieder (ORCID: https://orcid.org/0000-0001-6059-198X)
- Kaj Blennow (ORCID: https://orcid.org/0000-0002-1890-4193)
- Christer Möller
- Niklas Mattsson (ORCID: https://orcid.org/0000-0002-8885-7724)
- Oskar Hansson (ORCID: https://orcid.org/0000-0001-8467-7286)
- Eleni Gkanatsiou (ORCID: https://orcid.org/0000-0003-4443-2836)
- Gemma Salvadó (ORCID: https://orcid.org/0000-0002-5210-9230)
- Gunnar K. Gouras (ORCID: https://orcid.org/0000-0002-5500-6325)
- Tomas Deierborg (ORCID: https://orcid.org/0000-0002-3651-3444)
- Junyue Ge (ORCID: https://orcid.org/0009-0005-9542-802X)
- Henrik Zetterberg (ORCID: https://orcid.org/0000-0003-3930-4354)
- Shorena Janelidze (ORCID: https://orcid.org/0000-0003-2869-8378)
- Nils Lindblom
- Emelie Andersson
- Linda Söderberg
Institutions
- Uppsala University (SE)
- University of Wisconsin–Madison (US)
- Lund University (SE)
- Sahlgrenska University Hospital (SE)
- UK Dementia Research Institute (GB)
- Skåne University Hospital (SE)
- BioArctic Neuroscience (Sweden) (SE)
- National Hospital for Neurology and Neurosurgery (GB)
- University College London (GB)
- University of Gothenburg (SE)
Publication Details
- Journal
- Nature Aging
- Published
- 2025-02-12
- DOI
- https://doi.org/10.1038/s43587-025-00810-8
- Citations
- 26
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 30.27
Funders
- Alzheimer's Association
- Cure Alzheimer's Fund
- Australian Government
- GHR Foundation
- Lunds Universitet
- Knut och Alice Wallenbergs Stiftelse
- Vetenskapsrådet
- Skånes universitetssjukhus
- Parkinsonfonden